Arthroscopic knee surgery is a surgical procedure that can diagnose and treat problems in the knee joint. Patients with knee pain are managed on a day-case basis; therefore, appropriate postoperative pain relief is critical to facilitate patient discharge and early recovery.
Intra-articular administration of dexmedetomidine (DEX) improved pain outcomes in the early postoperative period after knee arthroscopy
Intra-articular injections of hyaluronic acid (HA) used in a 2–4 injection treatment regimen provided the greatest benefit when compared to IA-Saline with respect to pain improvement in patients with knee osteoarthritis (OA), and was generally deemed safe with few or no treatment-related adverse events (Aes) reported across studies.
Knee OA is a chronic inflammatory joint disorder with an estimated prevalence of 250 million people worldwide. It is characterized by joint pain, cartilage degeneration, and inflammation at the joints.
The analysis discovers moderate – quality evidence regarding manipulation and mobilization therapies role in lessening pain and disability with complete safety.
Low back pain is counting among the diseases which cause most devastation in a person's life. About 23% of the population suffering from low back pain. Out of which, 11%–12% population exhibit disability due to severe pain.
There is moderate-to high-quality evidence that anticonvulsants are ineffective for the treatment of low back pain or lumbar radicular pain. There is high-quality evidence that gabapentinoids have a higher risk of adverse events.
Globally, millions of people are suffered from low back pain (LBP) and become a major cause of disability than any other health complication. It is predicted that about 5% to 10% of patients with LBP have sciatica and followed by leg pain.
There were no significant differences in the primary outcomes and change in Health Assessment Questionnaire (HAQ), although the mean change in modified Total Sharp Score (mTSS) was 0.25 units (95 % CI, 0.01 to 0.49; P=0.04) higher in low-dose group at week 52. The author observed no significant difference in the median reduction in IgG levels between the study group.
We have previously published a systematic review and meta-analysis (SRMA) comparing low- versus high-dose rituximab (RTX) for the treatment of rheumatoid arthritis (RA), which showed no significant differences in primary efficacy outcomes between the two RTX schemes.
- 1 of 2